Switch theme
Sign up to access all valuation multiples
Nuvectis Pharma Inc is a biopharmaceutical company. The company is engaged in the development of innovative precision medicines for the treatment of serious conditions of unmet medical needs in oncology. It operates with one segment, focused on the development of novel targeted small molecule therapeutics for the treatment of cancer in genetically defined patient populations. Its pipeline products include NXP800, NXP900.
2020
13
LTM Revenue n/a
LTM EBITDA -$22.2M
$210M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Nuvectis Pharma has a last 12-month revenue of n/a and a last 12-month EBITDA of -$22.2M.
In the most recent fiscal year, Nuvectis Pharma achieved revenue of n/a and an EBITDA of -$19.8M.
Nuvectis Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Nuvectis Pharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$22.9M | -$19.8M | XXX | XXX | XXX |
| EBITDA Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Profit | -$19.1M | -$22.3M | XXX | XXX | XXX |
| Net Margin | -Infinity% | -Infinity% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Nuvectis Pharma's stock price is $10.
Nuvectis Pharma has current market cap of $229M, and EV of $210M.
See Nuvectis Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $210M | $229M | XXX | XXX | XXX | XXX | $-1.08 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Nuvectis Pharma has market cap of $229M and EV of $210M.
Nuvectis Pharma's trades at n/a LTM EV/Revenue multiple, and -9.5x LTM EBITDA.
Analysts estimate Nuvectis Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Nuvectis Pharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $210M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | -10.6x | XXX | XXX | XXX |
| P/E | -12.0x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -17.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpNuvectis Pharma's NTM/LTM revenue growth is n/a
Nuvectis Pharma's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $1.5M for the same period.
Over next 12 months, Nuvectis Pharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Nuvectis Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Nuvectis Pharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | -13% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | n/a | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.5M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | n/a | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nuvectis Pharma acquired XXX companies to date.
Last acquisition by Nuvectis Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Nuvectis Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Nuvectis Pharma founded? | Nuvectis Pharma was founded in 2020. |
| Where is Nuvectis Pharma headquartered? | Nuvectis Pharma is headquartered in United States of America. |
| How many employees does Nuvectis Pharma have? | As of today, Nuvectis Pharma has 13 employees. |
| Who is the CEO of Nuvectis Pharma? | Nuvectis Pharma's CEO is Mr. Ron Bentsur. |
| Is Nuvectis Pharma publicy listed? | Yes, Nuvectis Pharma is a public company listed on NAS. |
| What is the stock symbol of Nuvectis Pharma? | Nuvectis Pharma trades under NVCT ticker. |
| When did Nuvectis Pharma go public? | Nuvectis Pharma went public in 2022. |
| Who are competitors of Nuvectis Pharma? | Similar companies to Nuvectis Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Nuvectis Pharma? | Nuvectis Pharma's current market cap is $229M |
| What is the current EBITDA of Nuvectis Pharma? | Nuvectis Pharma's last 12-month EBITDA is -$22.2M. |
| What is the current EV/EBITDA multiple of Nuvectis Pharma? | Current EBITDA multiple of Nuvectis Pharma is -9.5x. |
| Is Nuvectis Pharma profitable? | Yes, Nuvectis Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
